Outlook Therapeutics Nasdaq/NYSE Compliance Notice
Outlook Therapeutics received a deficiency notice from Nasdaq on September 25, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has 180 calendar days, until March 24, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. If compliance is not met, the company may be eligible for an additional 180-day period or face potential delisting.
- Counterparty
- The Nasdaq Stock Market LLC
- Term
- 180 days